Braxia Scientific Corp has announced the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario, its fifth location in Canada.
The medical research company said its group of clinics, led by top researchers in depression Dr Roger McIntyre and Dr Joshua Rosenblat, provide patients greater access to Braxia's network of physicians, specialists and researchers delivering innovative, rapid acting treatments like intravenous (IV) and oral ketamine, and psilocybin for treatment resistant depression (TRD) and other mental health disorders.
“Today's announcement is the first of what we intend to be a series of growth developments and acquisitions to our clinical network,” Braxia Scientific CEO Roger McIntyre said in a statement.
READ: Braxia Scientific reports promising preliminary results from Phase 2 of its psilocybin-assisted therapy trial for treatment-resistant depression
“Further plans are in place for the expansion of Braxia Health clinics in Toronto and Ottawa, Ontario to better serve the growing unmet need in our Canadian communities,” McIntyre added.
Braxia noted the capacity expansion at its new flagship Toronto centre and Ottawa clinic is in response to demand amidst the evolving healthcare dynamic resulting from the coronavirus (COVID-19) pandemic, along with the ongoing Phase 2 multi-dose psilocybin trial in treatment resistant depression that reported positive preliminary results.
It added that Braxia specialists have delivered psilocybin treatments to patients through its ongoing multi-dose clinical trial – first-ever Health Canada approved multi-dose psilocybin trial – and, in conjunction with Health Canada special access program (SAP) allowing psilocybin to be prescribed by physicians on a case-by-case basis to patients in need.
To date, Braxia said it has treated multiple patients with psilocybin through its ongoing multi-dose clinical trial and training of 20 therapists via the Braxia Institute for psilocybin assisted therapy.
Canadians interested in applying to the SAP to participate in clinical trials or to qualify for other treatments such as IV and oral Ketamine for the treatment of depression may contact the medical team at Braxia Health at www.braxiahealth.com.
Braxia Scientific is a Toronto-based medical research company operating clinics that provide and advance innovative treatments for people living with depression and related mental health disorders.
Contact Sean at sean@proactiveinvestors.com